Rituxan (rituximab) - Roche
LAMA5 pathogenic variant uncovers a novel autoantigen in membranous nephropathy. (PubMed, Genes Dis) - Sep 21, 2026 - "Notably, rituximab treatment in the patient led to the disappearance of anti-Laminin α5 autoantibodies and sustained clinical remission. Our findings establish Laminin α5 as a novel genetic autoantigen in membranous nephropathy and suggest that screening for anti-Laminin α5 antibodies may help identify patients who could benefit from B-cell-targeted therapies." 
Journal • Glomerulonephritis • Nephrology • Pediatrics • Renal Disease • LAMA5
http://www.ncbi.nlm.nih.gov/pubmed/42763546
 
Chenyang Xiong; Haiping Yang; Han Xiao; Hui Yin; Lan Qiu; Qinqin Tan; Qiu Li; Wanbing Chen; Wei Jiang; Xindi Zhou; Xuejun Yang; Yulu Shi
 
Sep 21, 2026
 
Prev Next